From invention to adoption: the work between

The better future is not invention alone. It is useful change that survives contact with reality.

An invention can be scientifically interesting, technically elegant or commercially promising and still fail to alter practice. The gap is rarely one missing presentation. People need evidence they can trust, authority to act, resources to implement, a route through competing systems and confidence that the change will be supported when exceptions appear. My Financial Times letter focused on the test between invention and adoption. This reflection develops the operating question without reproducing the paywalled letter.

The award announcement should start a public conversion record.

That is why I am publishing the NEUVIOR Innovation Conversion Ledger alongside this reflection. It asks programme owners to follow funded cohorts into paid operational testing, repeat procurement, evidence led stopping and documented learning, where disclosure and programme design permit. It is a reporting proposal, not a claim about NEUVIOR’s results, and it does not position PHARMORIS as the answer.

Adoption is a sequence of decisions, not a launch event.

Different people decide whether a proposition is relevant, safe, affordable, procurable, implementable and worth continuing. Their decisions may happen at different levels and on different evidence. Calling the whole sequence ‘adoption’ hides the work and makes failure difficult to diagnose. A stronger model names each decision, the authorised owner, the input required, the possible outcomes and the route for escalation. It also preserves non adoption and deferral as legitimate results rather than treating every hesitation as resistance.

Design implementation while the proposition can still change.

Many implementation problems are discovered after the product or programme has become expensive to alter. You can bring those questions forward. What existing workflow will change? Which information is required, and can it be accessed responsibly? Who handles exceptions, downtime and conflicting evidence? What training, assurance, integration and local adaptation will be needed? A proposition that cannot answer these questions may still be worth exploring, but the unknowns belong in the design record and commercial plan from the beginning.

Give the adopter evidence and control, not only a promise.

The person asked to change carries consequences the inventor may never see. They need to know what the proposition does, what it does not do, how it was evaluated, where judgement remains human, what happens when it fails and who is accountable for support. This is why product evidence, governance, service design and commercial communication should be built together. Trust grows when the adopter can inspect the limits and retain meaningful control over the decision.

Measure continuation separately from initial uptake.

A signed agreement, enabled account or first use can each be useful milestones without proving sustained adoption or value. Review should examine whether the intended users continue, whether exceptions are resolved, whether the operating burden is understood and whether the result justifies the cost and risk. Measures need defined sources, baselines and owners. If the evidence is not yet available, the honest status is that the outcome remains unknown, not that the promise should be repeated until it sounds established.

The publication and evidence boundaries are explicit.

A founder letter is a published viewpoint, not Financial Times endorsement or staff reporting. Neither the letter nor this reflection demonstrates NEUVIOR customer adoption, deployment, regulatory approval, clinical efficacy, savings or healthcare outcomes. The work ahead is to earn each stage with evidence and let the operating record show what has, and has not, changed. The archived source record retains the publisher’s original byline.